Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seagen Inc (NQ: SGEN )

212.72 -0.49 (-0.23%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Seagen Inc

< Previous 1 2 3 4 5 Next >
European Commission Approves PADCEV™ (enfortumab vedotin) for Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Announces Jury Award in Patent Infringement Case Against Daiichi Sankyo
From Seagen Inc.
Via Business Wire
Seagen to Highlight Preclinical Data for Enfortumab Vedotin and Two Novel Antibody-Drug Conjugates at AACR Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Publishes Inaugural Corporate Responsibility Report
SOURCE: Seagen 
Via 3BL Media
Topics Emissions
Exposures Product Safety
Seagen to Host Conference Call and Webcast Discussion of First Quarter 2022 Financial Results on April 28, 2022
From Seagen Inc.
Via Business Wire
Seagen and Sanofi Announce Collaboration to Develop and Commercialize Multiple Novel Antibody-Drug Conjugates
From Seagen Inc.
Via Business Wire
Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen and Genmab Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Seagen Inc.
Via Business Wire
Genmab and Seagen Present First Data on Tisotumab Vedotin (TIVDAK®) in Patients with Head and Neck Squamous Cell Carcinoma
From Genmab A/S
Via Business Wire
Seagen and Astellas Announce Initial Results of PADCEV® (enfortumab vedotin-ejfv) in Patients With Muscle-Invasive Bladder Cancer Not Eligible for Cisplatin Chemotherapy
From Seagen Inc.
Via Business Wire
Seagen Reports Fourth Quarter and Full Year 2021 Financial Results
From Seagen Inc.
Via Business Wire
Seagen to Present at the 11th Annual SVB Leerink Global Healthcare Conference
From Seagen Inc.
Via Business Wire
ADCETRIS® Combination Significantly Improves Overall Survival in Newly Diagnosed Patients with Advanced Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer
Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials... 
Via FinancialNewsMedia
Seagen Appoints Lee Heeson as Executive Vice President, Commercial International
From Seagen Inc.
Via Business Wire
Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI)
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2021 Financial Results on February 9, 2022
From Seagen Inc.
Via Business Wire
Seagen to Present at the J.P. Morgan Healthcare Conference
From Seagen Inc.
Via Business Wire
Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen Announces Preliminary Results from Phase 2 Clinical Trial of ADCETRIS® (brentuximab vedotin) in Novel Combination of Agents for Patients with Advanced Stage Classical Hodgkin Lymphoma
From Seagen Inc.
Via Business Wire
Seagen Announces Updated Results from Pivotal HER2CLIMB Trial Evaluating TUKYSA® (tucatinib) in Patients with HER2-Positive Breast Cancer with Brain Metastases
From Seagen Inc.
Via Business Wire
Seagen to Highlight New Data in Advanced Breast Cancer at 2021 San Antonio Breast Cancer Symposium
From Seagen, Inc.
Via Business Wire
Seagen to Highlight Two Novel Antibody-Drug Conjugates (ADCs) at the SITC 36th Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen to Highlight Multiple ADCETRIS® (brentuximab vedotin) Data Presentations at the Upcoming 2021 American Society of Hematology (ASH) Annual Meeting
From Seagen Inc.
Via Business Wire
Seagen Reports Third Quarter 2021 Financial Results
From Seagen Inc.
Via Business Wire
Seagen and Astellas Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) With Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion of Third Quarter 2021 Financial Results on October 28, 2021
From Seagen Inc.
Via Business Wire
Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA® (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
From Seagen Inc.
Via Business Wire
Japan’s MHLW Approves PADCEV® (enfortumab vedotin) for Advanced Urothelial Cancer
From Seagen Inc.
Via Business Wire
Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK™ (tisotumab vedotin-tftv) Approval
From Seagen Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.